NO975741D0 - Epoksy-steroidalaldosteronantagonist og antiotensin-II-antagonistkombinasjonsterapi for behandling av kongestiv hjertesvikt - Google Patents

Epoksy-steroidalaldosteronantagonist og antiotensin-II-antagonistkombinasjonsterapi for behandling av kongestiv hjertesvikt

Info

Publication number
NO975741D0
NO975741D0 NO975741A NO975741A NO975741D0 NO 975741 D0 NO975741 D0 NO 975741D0 NO 975741 A NO975741 A NO 975741A NO 975741 A NO975741 A NO 975741A NO 975741 D0 NO975741 D0 NO 975741D0
Authority
NO
Norway
Prior art keywords
antagonist
epoxy
treatment
steroidalaldosterone
antiotensin
Prior art date
Application number
NO975741A
Other languages
English (en)
Other versions
NO318184B1 (no
NO975741L (no
Inventor
John Charles Alexander
Joseph R Schuh
Richard J Gorczynski
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO975741D0 publication Critical patent/NO975741D0/no
Publication of NO975741L publication Critical patent/NO975741L/no
Application filed by Searle & Co filed Critical Searle & Co
Publication of NO318184B1 publication Critical patent/NO318184B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
NO19975741A 1995-06-07 2004-11-23 Kombinasjon innbefattende en epoksy-steroidal aldosteron antagonist og en angiotensin II antagonist NO318184B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48645695A 1995-06-07 1995-06-07
PCT/US1996/009335 WO1996040257A1 (en) 1995-06-07 1996-06-05 Epoxy-steroidal aldosterone antagonist and angiotensin ii antagonist combination therapy for treatment of congestive heart failure

Publications (3)

Publication Number Publication Date
NO975741D0 true NO975741D0 (no) 1997-12-05
NO975741L NO975741L (no) 1998-01-29
NO318184B1 NO318184B1 (no) 2005-02-14

Family

ID=23931955

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19975741A NO318184B1 (no) 1995-06-07 2004-11-23 Kombinasjon innbefattende en epoksy-steroidal aldosteron antagonist og en angiotensin II antagonist

Country Status (21)

Country Link
US (1) US6653306B1 (no)
EP (1) EP0831910B1 (no)
JP (1) JPH11507627A (no)
KR (1) KR100618466B1 (no)
CN (2) CN1142793C (no)
AT (1) ATE209047T1 (no)
AU (1) AU725689B2 (no)
BR (1) BR9609066A (no)
CA (1) CA2224079A1 (no)
CZ (1) CZ297975B6 (no)
DE (1) DE69617235T2 (no)
DK (1) DK0831910T3 (no)
ES (1) ES2167571T3 (no)
IL (1) IL122242A (no)
NO (1) NO318184B1 (no)
NZ (1) NZ310730A (no)
PL (1) PL185150B1 (no)
PT (1) PT831910E (no)
RO (1) RO118046B1 (no)
RU (1) RU2166330C2 (no)
WO (1) WO1996040257A1 (no)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE243515T1 (de) * 1997-01-10 2003-07-15 Merck & Co Inc Verwendung der angiotensin ii-antagonisten losartan und exp-3174 zur behandlung von symptomatisches herzversagen
US6201002B1 (en) 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
US6306826B1 (en) 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
MXPA01009035A (es) * 1999-03-05 2004-08-12 Searle Llc Terapia de combinacion de inhibidor de enzima convertidora de angiotensina y antagonista de aldosterona epoxi-esteroidea para tratamiento de enfermedad cardiovascular.
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
US20030083342A1 (en) * 2002-08-27 2003-05-01 Steele Ronald Edward Combination of organic compounds
US20020132001A1 (en) * 2000-05-11 2002-09-19 Garthwaite Susan M. Aldosterone antagonist composition for release during aldosterone acrophase
WO2002009761A2 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
CA2415078A1 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
CA2469435A1 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
WO2003077892A2 (en) * 2002-03-15 2003-09-25 Novartis Ag 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide for treating ang ii-mediated diseases
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
US20050153885A1 (en) * 2003-10-08 2005-07-14 Yun Anthony J. Treatment of conditions through modulation of the autonomic nervous system
WO2005039637A2 (en) * 2003-10-17 2005-05-06 Novartis Ag Combinations of an aldosterone receptor antagonist, a diuretic and an angiotensin blocker
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
JP2008520744A (ja) 2004-11-19 2008-06-19 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 抗炎症性ピラゾロピリミジン
CN101024643A (zh) * 2006-02-20 2007-08-29 上海艾力斯医药科技有限公司 咪唑－5－羧酸类衍生物、制备方法及其应用
NZ571182A (en) 2006-04-04 2010-09-30 Univ California Pyrazolo[3,4-d]pyrimidines
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
NZ587051A (en) 2008-01-04 2012-12-21 Intellikine Llc Isoquinolinone derivatives, compositions and methods of inhibiting phosphatidyl inositol-3 kinase (pi3 kinase)
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
ES2570429T3 (es) 2008-10-16 2016-05-18 Univ California Inhibidores de heteroaril quinasa de anillo condensado
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
ES2433225T3 (es) 2009-01-30 2013-12-10 Takeda Pharmaceutical Company Limited Compuesto con anillos condensados y uso del mismo
CA2760791C (en) 2009-05-07 2017-06-20 Intellikine, Inc. Heterocyclic compounds and uses thereof
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
ES2593256T3 (es) 2010-05-21 2016-12-07 Infinity Pharmaceuticals, Inc. Compuestos químicos, composiciones y métodos para las modulaciones de cinasas
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN103648499B (zh) 2011-01-10 2017-02-15 无限药品股份有限公司 用于制备异喹啉酮的方法及异喹啉酮的固体形式
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
CA2842190A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013032591A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CA2846496C (en) 2011-09-02 2020-07-14 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
JP2015532287A (ja) 2012-09-26 2015-11-09 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｉｒｅ１の調節
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CA2925944C (en) 2013-10-04 2023-01-10 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP4066834A1 (en) 2014-03-19 2022-10-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017223422A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
CN109715615A (zh) 2016-06-29 2019-05-03 蒙特利尔大学 联芳甲基杂环
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11971205B2 (en) 2021-08-20 2024-04-30 Pioneer Family Brands, Inc. Ice shaver with splash guard

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI77669C (fi) * 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
CA2053148A1 (en) * 1990-10-16 1992-04-17 Karnail Atwal Dihydropyrimidine derivatives
US5049565A (en) * 1990-12-07 1991-09-17 Merck & Co., Inc. Microbial transformation process for preparing anti-hypertensive products
WO1992020662A1 (en) * 1991-05-10 1992-11-26 Merck & Co., Inc. Acidic aralkyl triazole derivatives active as angiotensin ii antagonists
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
US6008210A (en) * 1992-04-21 1999-12-28 Weber; Karl T. Use of aldosterone antagonists to inhibit myocardial fibrosis
WO1994009778A1 (en) * 1992-10-26 1994-05-11 Merck & Co., Inc. Combinations of angiotensin-ii receptor antagonists and diuretics
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases

Also Published As

Publication number Publication date
NO318184B1 (no) 2005-02-14
CZ385097A3 (cs) 1998-06-17
NO975741L (no) 1998-01-29
PL185150B1 (pl) 2003-03-31
NZ310730A (en) 2001-01-26
CN1522701A (zh) 2004-08-25
AU6157796A (en) 1996-12-30
DK0831910T3 (da) 2002-05-21
DE69617235D1 (de) 2002-01-03
PT831910E (pt) 2002-05-31
IL122242A (en) 2001-07-24
BR9609066A (pt) 1999-01-26
ATE209047T1 (de) 2001-12-15
CA2224079A1 (en) 1996-12-19
KR100618466B1 (ko) 2006-12-13
EP0831910B1 (en) 2001-11-21
ES2167571T3 (es) 2002-05-16
CZ297975B6 (cs) 2007-05-09
US6653306B1 (en) 2003-11-25
EP0831910A1 (en) 1998-04-01
PL324001A1 (en) 1998-04-27
IL122242A0 (en) 1998-04-05
CN1142793C (zh) 2004-03-24
RU2166330C2 (ru) 2001-05-10
WO1996040257A1 (en) 1996-12-19
AU725689B2 (en) 2000-10-19
CN1192697A (zh) 1998-09-09
JPH11507627A (ja) 1999-07-06
KR19990022548A (ko) 1999-03-25
DE69617235T2 (de) 2002-07-25
RO118046B1 (ro) 2003-01-30

Similar Documents

Publication Publication Date Title
NO975741L (no) Epoksy-steroidalaldosteronantagonist og antiotensin-II-antagonistkombinasjonsterapi for behandling av kongestiv hjertesvikt
DK0831911T3 (da) Kombinationsterapi til behandling af kongestivt hjertesvigt med spironolacton og angiotensin II-antagonist
NO176049C (no) Analogifremgangsmåte for fremstilling av terapeutiske imidazoler som blokkerer angiotensin-II-reseptorer
EP2277519A3 (en) Use of Angiotensin II type 1 receptor antagonists for the prevention of stroke, diabetes and/or congestive heart failure
ITBO960478A0 (it) Procedimento per la stimolazione controllata di regioni predefinite del corpo umano tramite l'applicazione di segnali elettrici variabili
EP0959896A4 (en) COMPOSITIONS BASED ON THE HUMAN THYROTROPIN RECEPTOR AND THEIR USE
AU8844491A (en) Renal-selective biphenylalkyl 1h-substituted-1,2,4-triazole angiotensin ii antagonists for treatment of hypertension
AU1463792A (en) N-substituted (alpha-imidazolyl-toluyl) pyrrole angiotensin ii antagonists for treatment of circulatory disorders
NO990722D0 (no) FremgangsmÕte for behandling av hjertesvikt
AU8534291A (en) Renal-selective angiotensin ii antagonists for treatment of hypertension
AU4339896A (en) Treatment of hypertension and congestive heart failure
HK1022432A1 (en) Administration of histamine for therapeutic purposes.
AU3745795A (en) Use of CCK-B receptor antagonists for the treatment of sleepdisorders
NO932391D0 (no) Angiotensin-ii reseptorantagonister for behandling av hjerterytmeforstyrrelser
AU4163793A (en) Angiotensin II receptor antagonists for the treatment and prophylaxis of coronary heart disease
NO984432D0 (no) FremgangsmÕte for behandling av migrenesmerte
AU3635793A (en) Pyrazolopyrimidin derivatives as angiotensin II receptor antagonists
AU2003202486A1 (en) Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for the treatment of congestive heart failure
AU2003204258A1 (en) Spironolactone and angiotensin II antagonist combination therapy for treatment of congestive heart failure
NO955056L (no) Enantiomerer av 4-(5-fluor-2,3-dihydro-1H-inden-2-yl)-1H-imidazol
BR9607612A (pt) Terapia de combinaç o de inibidor de enzima de conversão de angiotensina quantidade de reduzido efeito colateral de antagonista da aldosterona e diurético par tratamento de doenças cardiovasculares
MX9710002A (es) Nuevo uso medico.
MX9709976A (es) Terapia de combinacion con espironolactona y antagonista de angiotensina ii para el tratamiento de fallas cardiacas congestivas.
AU2003202461A1 (en) Combination therapy of angiotensin converting enzyme inhibitor and side-effect-reduced amount of aldosterone antagonist for treatment of cardiovascular disease
FR2752736B1 (fr) Utilisation d'antagonistes 5-ht4 dans la regulation de la secretion de corticosteroides